Assessment of treatment with orotate magnesium in early postoperative period of patients with cardiac insufficiency and coronary artery by-pass grafts (ATOMIC)

The benefit of the treatment with magnesium orotate (magnerot) was assessed in a randomised, single blind and placebo controlled study. Respecting the inclusion criteria were selected 32 patients with ischemia chronic failure in early postoperative period after CABG. The main improvements induced by...

Full description

Saved in:
Bibliographic Details
Published inRevue roumaine de médecine interne (1990) Vol. 37; no. 3; p. 287
Main Authors Branea, I, Gaiţă, D, Drăgulescu, I, Socoteanu, I, Luca, C, Mancaş, S, Drăgan, S, Iurciuc, M, Velimirovici, D, Gaşpar, M, Fluture, A, Ionac, A, Deutsch, P, Pescariu, S, Petrescu, L, Branea, H, Mut, B, Dină, C, Crâsnic, M, Sarău, C A
Format Journal Article
LanguageEnglish
Published Germany 01.07.1999
Subjects
Adult
Aged
Coronary Artery Bypass
Echocardiography
Exercise Test
Female
Humans
Male
Middle Aged
Myocardial Ischemia - drug therapy
Orotic Acid - therapeutic use
Postoperative Complications - drug therapy
Quality of Life
Single-Blind Method
Online AccessGet more information

Cover

More Information
Summary:The benefit of the treatment with magnesium orotate (magnerot) was assessed in a randomised, single blind and placebo controlled study. Respecting the inclusion criteria were selected 32 patients with ischemia chronic failure in early postoperative period after CABG. The main improvements induced by magnesium orotate are the increase in exercise capacity (distance ambulated during 6 minutes walk test and ergospirometric parameters) and the reduction of ventricular premature beats. The treatment was well tolerated and the adverse reactions were not significant. The study strongly suggests the benefit of magnesium orotate added to classical antiischemic therapy in the complex management of coronary patients after CABG.
ISSN:1220-4749